A pilot trial of labetalol (AH 5158A): a combined alpha and beta blocker in treatment of hypertension.
Labetalol (5-1 hydroxy-2 (1-methyl-3 phenyl amino salicylamide hydrochloride)) is a new antihypertensive agent having partial alpha- and beta-adrenoreceptor-blocking properties. Nine patients with mild, moderate or severe hypertension have been given this drug over periods ranging from 6-29 weeks. Labetalol was given as replacement for a beta-blocking drug providing less than satisfactory control. Adequate control of blood pressure was achieved in all nine patients. The only side-effect of note was postural hypotension which necessitated withdrawal of the drug in one patient.
D000974:Antibodies, Antinuclear; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000276:immunology; D007741:Labetalol / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects
D000974:Antibodies, Antinuclear; D004983:Ethanolamines; D007741:Labetalol